Infigratinib

CHEMBL1852688 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

560.5 g/mol

LogP

4.7

Phase

4

This oral fibroblast growth factor receptor (FGFR) inhibitor is used to treat FGFR2 fusion-positive, locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer). It works by blocking FGFR2 signaling that drives tumor cell proliferation in patients with specific genetic alterations. Hyperphosphatemia (elevated blood phosphate) is a common side effect due to FGFR1 inhibition.

分子量

560.5000 g/mol

LogP

4.70

TPSA

95.10 Å²

リピンスキーの五則

適合

治療領域

Melanoma Pancreatic Cancer Bladder Cancer Breast Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1

InChI

InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)

Molecular Formula

C26H31Cl2N7O3

HBD / HBA

2 / 8

回転可能結合数

8

重原子数

38

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This oral fibroblast growth factor receptor (FGFR) inhibitor is used to treat FGFR2 fusion-positive, locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer). It works by blocking FGFR2 signaling that drives tumor cell proliferation in patients with specific genetic alterations. Hyperphosphatemia (elevated blood phosphate) is a common side effect due to FGFR1 inhibition.

Yes, Infigratinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1852688. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 53235510. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Infigratinib PillFYIで

構造

クイックデータ

分子式: C26H31Cl2N7O3

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.